An enzyme that catalyzes the reduction of a 3 beta-hydroxy-delta(5)-steroid to 3-oxo-delta(4)-steroid in the presence of NAD. It converts pregnenolone to progesterone and dehydroepiandrosterone to androstenedione. EC 1.1.1.145.
Oxidoreductases that are specific for the reduction of NITRATES.
Enzymes that catalyze the reversible reduction of alpha-carboxyl group of 3-hydroxy-3-methylglutaryl-coenzyme A to yield MEVALONIC ACID.
Ribonucleotide Reductases are enzymes that catalyze the conversion of ribonucleotides to deoxyribonucleotides, which is a crucial step in DNA synthesis and repair, utilizing a radical mechanism for this conversion.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
A FLAVOPROTEIN oxidoreductase that occurs both as a soluble enzyme and a membrane-bound enzyme due to ALTERNATIVE SPLICING of a single mRNA. The soluble form is present mainly in ERYTHROCYTES and is involved in the reduction of METHEMOGLOBIN. The membrane-bound form of the enzyme is found primarily in the ENDOPLASMIC RETICULUM and outer mitochondrial membrane, where it participates in the desaturation of FATTY ACIDS; CHOLESTEROL biosynthesis and drug metabolism. A deficiency in the enzyme can result in METHEMOGLOBINEMIA.
A group of enzymes that oxidize diverse nitrogenous substances to yield nitrite. (Enzyme Nomenclature, 1992) EC 1.
Catalyzes the oxidation of GLUTATHIONE to GLUTATHIONE DISULFIDE in the presence of NADP+. Deficiency in the enzyme is associated with HEMOLYTIC ANEMIA. Formerly listed as EC 1.6.4.2.
An enzyme that utilizes NADH or NADPH to reduce FLAVINS. It is involved in a number of biological processes that require reduced flavin for their functions such as bacterial bioluminescence. Formerly listed as EC 1.6.8.1 and EC 1.5.1.29.
A FLAVOPROTEIN enzyme that catalyzes the oxidation of THIOREDOXINS to thioredoxin disulfide in the presence of NADP+. It was formerly listed as EC 1.6.4.5
A flavoprotein that catalyzes the reduction of heme-thiolate-dependent monooxygenases and is part of the microsomal hydroxylating system. EC 1.6.2.4.
An enzyme that catalyzes the oxidation and reduction of FERREDOXIN or ADRENODOXIN in the presence of NADP. EC 1.18.1.2 was formerly listed as EC 1.6.7.1 and EC 1.6.99.4.
The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9)
The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE.
Cytochrome reductases are enzymes that catalyze the transfer of electrons from donor molecules to cytochromes in electron transport chains, playing a crucial role in cellular respiration and energy production within cells.
Steroidal compounds related to PROGESTERONE, the major mammalian progestational hormone. Progesterone congeners include important progesterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with progestational activities.
A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
The period in the ESTROUS CYCLE associated with maximum sexual receptivity and fertility in non-primate female mammals.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.
An enzyme of the oxidoreductase class that catalyzes the reaction 7,8-dihyrofolate and NADPH to yield 5,6,7,8-tetrahydrofolate and NADPH+, producing reduced folate for amino acid metabolism, purine ring synthesis, and the formation of deoxythymidine monophosphate. Methotrexate and other folic acid antagonists used as chemotherapeutic drugs act by inhibiting this enzyme. (Dorland, 27th ed) EC 1.5.1.3.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
The hollow thick-walled muscular organ in the female PELVIS. It consists of the fundus (the body) which is the site of EMBRYO IMPLANTATION and FETAL DEVELOPMENT. Beyond the isthmus at the perineal end of fundus, is CERVIX UTERI (the neck) opening into VAGINA. Beyond the isthmi at the upper abdominal end of fundus, are the FALLOPIAN TUBES.
The surgical removal of one or both ovaries.
The period in the MENSTRUAL CYCLE that follows OVULATION, characterized by the development of CORPUS LUTEUM, increase in PROGESTERONE production by the OVARY and secretion by the glandular epithelium of the ENDOMETRIUM. The luteal phase begins with ovulation and ends with the onset of MENSTRUATION.
A flavoprotein amine oxidoreductase that catalyzes the reversible conversion of 5-methyltetrahydrofolate to 5,10-methylenetetrahydrofolate. This enzyme was formerly classified as EC 1.1.1.171.
The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.
The process of bearing developing young (EMBRYOS or FETUSES) in utero in non-human mammals, beginning from FERTILIZATION to BIRTH.
The discharge of an OVUM from a rupturing follicle in the OVARY.
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Nicotinamide adenine dinucleotide phosphate. A coenzyme composed of ribosylnicotinamide 5'-phosphate (NMN) coupled by pyrophosphate linkage to the 5'-phosphate adenosine 2',5'-bisphosphate. It serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH). (Dorland, 27th ed)
An NAD-dependent enzyme that catalyzes the oxidation of nitrite to nitrate. It is a FLAVOPROTEIN that contains IRON and MOLYBDENUM and is involved in the first step of nitrate assimilation in PLANTS; FUNGI; and BACTERIA. It was formerly classified as EC 1.6.6.1.
Reductases that catalyze the reaction of peptide-L-methionine -S-oxide + thioredoxin to produce peptide-L-methionine + thioredoxin disulfide + H(2)O.
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.

Creation of a fully active, cytosolic form of human type I 3beta-hydroxysteroid dehydrogenase/isomerase by the deletion of a membrane-spanning domain. (1/71)

Human 3beta-hydroxysteroid dehydrogenase/steroid Delta(5)-Delta(4)-isomerase (3beta-HSD/isomerase) is a bifunctional, single enzyme protein that is membrane-bound in the endoplasmic reticulum (microsomes) and mitochondria of cells in the placenta (type I) and in the adrenals and gonads (type II). Two membrane-binding domains (residues 72-89 and 283-310) have been predicted by analyses of hydrophobicity in the type I and II isoenzymes (90% regional homology). These putative membrane domains were deleted in the cDNA by PCR-based mutagenesis, and the two mutant enzymes were expressed by baculovirus in insect Sf9 cells. Differential centrifugation of the Sf9 cell homogenate containing the 283-310 deletion mutant revealed that 94% of the 3beta-HSD and isomerase activities were in the cell cytosol, 6% of the activities were in the microsomes, and no activity was in the mitochondria. This is the opposite of the subcellular distribution of the wild-type enzyme with 94% of the activities in the microsomes and mitochondria and only 6% activity in the cytosol. The organelle distribution of the 72-89 deletion mutant lies between these two extremes with 72% of the enzyme activity in the cytosol and 28% in the microsomes/mitochondria. The integrity of the subcellular organelle preparations was confirmed by electron microscopy. Western immunoblots confirmed the presence of the 283-310 deletion mutant enzyme and the absence of the wild-type enzyme in the insect cell cytosol. The unpurified, cytosolic 383-310 deletion mutant exhibited 3beta-HSD (22 nmol/min per mg) and isomerase (33 nmol/min per mg) specific activities that were comparable with those of the membrane-bound, wild-type enzyme. The isomerase reaction of the cytosolic 283-311 deletion mutant requires activation by NADH just like the isomerase of the microsomal or mitochondrial wild-type enzyme. In contrast, the 72-89 deletion mutant had low 3beta-HSD and isomerase specific activities that were only 12% of the wild-type levels. This innovative study identifies the 283-310 region as the critical membrane domain of 3beta-HSD/isomerase that can be deleted without compromising enzyme function. The shorter 72-89 region is also a membrane domain, but deletion of this NH(2)-terminal region markedly diminishes the enzyme activities. Purification of the active, cytosolic 283-310 deletion mutant will produce a valuable tool for crystallographic studies that may ultimately determine the tertiary/quaternary structure of this key steroidogenic enzyme.  (+info)

The engineered, cytosolic form of human type I 3beta-hydroxysteroid dehydrogenase/isomerase: purification, characterization and crystallization. (2/71)

Human type I 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD/isomerase) is an integral membrane protein of human placental trophoblast and of insect Sf9 cells transfected with recombinant baculovirus containing the cDNA encoding the enzyme. Purified native or wild-type enzyme remains in solution only in the presence of detergent that may prevent crystallization. The membrane-spanning domain (residues 283-310) of the enzyme protein was deleted in the cDNA using PCR-based mutagenesis. The modified enzyme was expressed by baculovirus in the cytosol instead of in the microsomes and mitochondria of the Sf9 cells. The cytosolic form of 3beta-HSD/isomerase was purified using affinity chromatography with Cibacron Blue 1000. The NAD(+) and NaCl used to elute the enzyme were removed by size-exclusion centrifugation. Hydroxylapatite chromatography yielded a 26-fold purification of the enzyme. SDS-PAGE revealed a single protein band for the purified cytosolic enzyme (monomeric molecular mass 38.8 kDa) that migrated just below the wild-type enzyme (monomeric molecular mass 42.0 kDa). Michaelis-Menten constants measured for 3beta-HSD substrate (dehydroepiandrosterone) utilization by the purified cytosolic enzyme (K(m)=4.5 microM, V(max)=53 nmol/min per mg) and the pure wild-type enzyme (K(m)=3.7 microM, V(max)=43 nmol/min per mg), for isomerase substrate (5-androstene-3,17-dione) conversion by the purified cytosolic (K(m)=25 microM, V(max)=576 nmol/min per mg) and wild-type (K(m)=28 microM, V(max)=598 nmol/min per mg) enzymes, and for NAD(+) reduction by the 3beta-HSD activities of the cytosolic (K(m)=35 microM, V(max)=51 nmol/min per mg) and wild-type (K(m)=34 microM, V(max)=46 nmol/min per mg) enzymes are nearly identical. The isomerase activity of the cytosolic enzyme requires allosteric activation by NADH (K(m)=4.6 microM, V(max)=538 nmol/min per mg) just like the wild-type enzyme (K(m)=4.6 microM, V(max)=536 nmol/min per mg). Crystals of the purified, cytosolic enzyme protein have been obtained. The inability to crystallize the detergent-solubilized, wild-type microsomal enzyme has been overcome by engineering a cytosolic form of this protein. Determining the tertiary structure of 3beta-HSD/isomerase will clarify the mechanistic roles of potentially critical amino acids (His(261), Tyr(253)) that have been identified in the primary structure.  (+info)

Expression of connexin43 in mouse Leydig, Sertoli, and germinal cells at different stages of postnatal development. (3/71)

Connexin 43 (Cx43) is the most abundant and ubiquitously distributed gap junction protein in testicular cells. Lack of Cx43 expression results in male infertility. We investigated whether Cx43 is expressed and regulated in Leydig, Sertoli and germinal cells at different stages of postnatal development. Cx43 was detected using three different antibodies shown by immunoblotting to be highly specific. At different postnatal ages Cx43 localization was compared in serial or double labeled testicular cryosections with immunocytochemical distribution of steroidogenic enzyme, 3 betahydroxysteroid-dehydrogenase (3betaHSD), Mullerian inhibitory hormone (MIH), and germinal nuclear cell antigen (GNCA1), which are specific markers of interstitial Leydig, Sertoli and germinal cells, respectively. In the interstitium, round cell clumps (RCC) with lipid droplets positive for 3betaHSD and Cx43 were frequently found at intertubular areas at birth and Cx43 was mainly localized at cell membrane appositions. From day 3, the number and size of 3betaHSD-positive RCC started to decrease, and reached a minimum at 7-14 dpp; Cx43 expressed by them is progressively downregulated. From day 21 an increase in the size and number of RCC positive for Cx43 and 3betaHSD was found that continued at 24, 26 and 28 days and reached a maximum at 35 and 60 dpp. Biphasic expression of interstitial Cx43 and 3betaHSD was also found to be positively and temporally correlated with fluctuations in intratesticular testosterone content at all ages studied. In the seminiferous cord (SC), Cx43 was expressed at birth between adjacent Sertoli cells (MIH positive) localized at the periphery, as well as in their cytoplasm projections that surround centrally localized gonocytes. From days 3 to 7, Cx43 labeling increased in Sertoli cells mainly at their apical border. At day 14, Cx43 distribution in Sertoli cells changed from apical to basal in parallel to migration of germinal (GNCA1-positive) cells from the periphery to the center of the SC. At all these ages, Cx43 was also localized at cell borders between Sertoli and germinal cells. In conclusion, this study demonstrates that Cx43 in Leydig cells is regulated during postnatal development in an age and functional dependent manner. In the tubule, it is demonstrated that Cx43 is modulated in Sertoli cells during the neonatal and prepubertal period. We also provide evidence for the first time that Cx43-gap junctions communicate between Sertoli and germinal cells before and during the first wave of spermatogenesis.  (+info)

Expression of key enzymes in bile acid biosynthesis during development: CYP7B1-mediated activities show tissue-specific differences. (4/71)

The developmental variation of cytochrome P450 (CYP)7A1, CYP7B1, CYP27A1, and 3beta-hydroxy-Delta(5)-C(27)-steroid dehydrogenase, key enzymes in bile acid biosynthesis, were investigated in pigs of different ages. As part of these studies, peptide sequences from a purified pig liver oxysterol 7alpha-hydroxylase were analyzed. The sequences showed a high degree of identity with those of murine and human CYP7B1. Enzymatic activities and mRNA levels of CYP27A1 and 3beta-hydroxy-Delta(5)-C(27)-steroid dehydrogenase were similar in livers of newborn and 6-month-old pigs. Enzymatic activity mediated by CYP7A1 increased several-fold between infancy and adolescence. Hepatic CYP7A1 and CYP7B1 mRNA levels increased several-fold with age. Hepatic microsomal 7alpha-hydroxylation of 27-hydroxycholesterol and dehydroepiandrosterone, substrates typical for CYP7B1, increased about 5-fold between infancy and adolescence whereas the activities in kidney microsomes decreased at least 10-fold. In conclusion, the results indicate that the expression of CYP27A1 and 3beta-hydroxy-Delta(5)-C(27)-steroid dehydrogenase are similar in livers of newborn and 6-month-old pigs whereas the levels of CYP7A1 increase. The finding that the levels of CYP7B1 increase with age in the liver but decrease in the kidney suggest a tissue-specific developmental regulation of CYP7B1. The age-dependent variation in the liver and kidney suggests that hormonal factors are involved in the regulation of CYP7B1.  (+info)

Regulation of steroidogenic genes by insulin-like growth factor-1 and follicle-stimulating hormone: differential responses of cytochrome P450 side-chain cleavage, steroidogenic acute regulatory protein, and 3beta-hydroxysteroid dehydrogenase/isomerase in rat granulosa cells. (5/71)

The present study sought to characterize the concerted action of FSH and insulin-like growth factor-1 (IGF-1) on functional differentiation of prepubertal rat ovarian granulosa cells in culture. To this end, we examined the regulation of three key genes encoding pivotal proteins required for progesterone biosynthesis, namely, side-chain cleavage cytochrome P450 (P450(scc)), steroidogenic acute regulatory (StAR) protein, and 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD). Time-dependent expression profiles showed that P450(scc), StAR, and 3beta-HSD gene products accumulate in chronic, acute, and constitutive patterns, respectively. Each of these genes responded to FSH and/or IGF-1 in a characteristic manner: A synergistic action of IGF-1 was indispensable for FSH induction of P450(scc) mRNA and protein; IGF-1 did not affect FSH-mediated upregulation of StAR products; and IGF-1 alone was enough to promote expression of 3beta-HSD. The responsiveness of the genes to IGF-1 correlated well with their apparent susceptibility to the inhibitory impact of tyrphostin AG18, a potent inhibitor of protein tyrosine kinase receptors. Thus, IGF-1-dependent P450(scc) and 3beta-HSD expression was completely arrested in the presence of AG18, whereas StAR expression was unaffected in the presence of tyrphostin. These findings suggest that FSH/cAMP signaling and IGF-1/tyrosine phosphorylation events are interwoven in rat ovarian cells undergoing functional differentiation. We also sought the mechanism of IGF-1 synergy with FSH. In this regard, our studies were unable to demonstrate a stabilizing effect of IGF-1 on P450(scc) mRNA, nor could IGF-1 augment FSH-induced transcription examined using a proximal region of the P450(scc) promoter (-379/+6). Thus, the mechanism of IGF-1 and FSH synergy remains enigmatic and provides a major challenge for future studies.  (+info)

Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. (6/71)

Two distinct genes encode the 93% homologous type 1 (placenta, peripheral tissues) and type 2 (adrenals, gonads) 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD/isomerase) in humans. Mutagenesis studies using the type 1 enzyme have produced the Y154F and K158Q mutant enzymes in the Y(154)-P-H(156)-S-K(158) motif as well as the Y269S and K273Q mutants from a second motif, Y(269)-T-L-S-K(273), both of which are present in the primary structure of the human type 1 3beta-HSD/isomerase. In addition, the H156Y mutant of the type 1 enzyme has created a chimera of the type 2 enzyme motif (Y(154)-P-Y(156)-S-K(158)) in the type 1 enzyme. The mutant and wild-type enzymes have been expressed and purified. The K(m) value of dehydroepiandrosterone is 13-fold greater, and the maximal turnover rate (K(cat)) is 2-fold greater for wild-type 2 3beta-HSD compared with the wild-type 1 3beta-HSD activity. The H156Y mutant of the type 1 enzyme has substrate kinetic constants for 3beta-HSD activity that are very similar to those of the wild-type 2 enzyme. Dixon analysis shows that epostane inhibits the 3beta-HSD activity of the wild-type 1 enzyme with 14-17-fold greater affinity compared with the wild-type 2 and H156Y enzymes. The Y154F and K158Q mutants exhibit no 3beta-HSD activity, have substantial isomerase activity, and utilize substrate with K(m) values similar to those of wild-type 1 isomerase. The Y269S and K273Q mutants have low, pH-dependent 3beta-HSD activity, exhibit only 5% of the maximal isomerase activity, and utilize the isomerase substrate very poorly. From these studies, a structural basis for the profound differences in the substrate and inhibition kinetics of the wild-type 1 and 2 3beta-HSD, plus a catalytic role for the Tyr(154) and Lys(158) residues in the 3beta-HSD reaction have been identified. These advances in our understanding of the structure/function of human type 1 and 2 3beta-HSD/isomerase may lead to the design of selective inhibitors of the type 1 enzyme not only in placenta to control the onset of labor but also in hormone-sensitive breast, prostate, and choriocarcinoma tumors to slow their growth.  (+info)

Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2. (7/71)

In mammals, Sry expression in the bipotential, undifferentiated gonad directs the support cell precursors to differentiate as Sertoli cells, thus initiating the testis differentiation pathway. In the absence of Sry, or if Sry is expressed at insufficient levels, the support cell precursors differentiate as granulosa cells, thus initiating the ovarian pathway. The molecular mechanisms upstream and downstream of Sry are not well understood. We demonstrate that the transcription factor GATA4 and its co-factor FOG2 are required for gonadal differentiation. Mouse fetuses homozygous for a null allele of Fog2 or homozygous for a targeted mutation in Gata4 (Gata4(ki)) that abrogates the interaction of GATA4 with FOG co-factors exhibit abnormalities in gonadogenesis. We found that Sry transcript levels were significantly reduced in XY Fog2(-/-) gonads at E11.5, which is the time when Sry expression normally reaches its peak. In addition, three genes crucial for normal Sertoli cell function (Sox9, Mis and Dhh) and three Leydig cell steroid biosynthetic enzymes (p450scc, 3betaHSD and p450c17) were not expressed in XY Fog2(-/-) and Gata(ki/ki) gonads, whereas Wnt4, a gene required for normal ovarian development, was expressed ectopically. By contrast, Wt1 and Sf1, which are expressed prior to Sry and necessary for gonad development in both sexes, were expressed normally in both types of mutant XY gonads. These results indicate that GATA4 and FOG2 and their physical interaction are required for normal gonadal development.  (+info)

Structure/function relationships responsible for coenzyme specificity and the isomerase activity of human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase. (8/71)

Human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase (3 beta-HSD/isomerase) catalyzes the two sequential enzyme reactions on a single protein that converts dehydroepiandrosterone or pregnenolone to androstenedione or progesterone, respectively, in placenta, mammary gland, breast tumors, prostate, prostate tumors, and other peripheral tissues. Our earlier studies show that the two enzyme reactions are linked by the coenzyme product, NADH, of the 3 beta-HSD activity. NADH activates the isomerase activity by inducing a time-dependent conformational change in the enzyme protein. The current study tested the hypothesis that the 3 beta-HSD and isomerase activities shared a common coenzyme domain, and it characterized key amino acids that participated in coenzyme binding and the isomerase reaction. Homology modeling with UDP-galactose-4-epimerase predicts that Asp36 is responsible for the NAD(H) specificity of human 3 beta-HSD/isomerase and identifies the Rossmann-fold coenzyme domain at the amino terminus. The D36A/K37R mutant in the potential coenzyme domain and the D241N, D257L, D258L, and D265N mutants in the potential isomerase domain (previously identified by affinity labeling) were created, expressed, and purified. The D36A/K37R mutant shifts the cofactor preference of both 3 beta-HSD and isomerase from NAD(H) to NADP(H), which shows that the two activities utilize a common coenzyme domain. The D257L and D258L mutations eliminate isomerase activity, whereas the D241N and D265N mutants have nearly full isomerase activity. Kinetic analyses and pH dependence studies showed that either Asp257 or Asp258 plays a catalytic role in the isomerization reaction. These observations further characterize the structure/function relationships of human 3 beta-HSD/isomerase and bring us closer to the goal of selectively inhibiting the type 1 enzyme in placenta (to control the timing of labor) or in hormone-sensitive breast tumors (to slow their growth).  (+info)

Progesterone reductase is not a widely recognized or used term in medical literature. However, based on the terms "progesterone" and "reductase," it can be inferred that progesterone reductase might refer to an enzyme responsible for reducing or converting progesterone into another form through a reduction reaction.

Progesterone is a steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis. Reductases are enzymes that catalyze the transfer of electrons from a donor to an acceptor, often resulting in the reduction of a substrate. In this context, progesterone reductase could potentially refer to an enzyme responsible for reducing progesterone into a different steroid hormone or metabolite.

However, it is essential to note that there is no widely accepted or established definition of "progesterone reductase" in medical literature. If you are looking for information on a specific enzyme related to progesterone metabolism, I would recommend consulting primary scientific literature or seeking guidance from a medical professional.

Nitrate reductases are a group of enzymes that catalyze the reduction of nitrate (NO3-) to nitrite (NO2-). This process is an essential part of the nitrogen cycle, where nitrate serves as a terminal electron acceptor in anaerobic respiration for many bacteria and archaea. In plants, this enzyme plays a crucial role in nitrogen assimilation by reducing nitrate to ammonium (NH4+), which can then be incorporated into organic compounds. Nitrate reductases require various cofactors, such as molybdenum, heme, and/or FAD, for their activity. There are three main types of nitrate reductases: membrane-bound (which use menaquinol as an electron donor), cytoplasmic (which use NADH or NADPH as an electron donor), and assimilatory (which also use NADH or NADPH as an electron donor).

Hydroxymethylglutaryl CoA (HMG-CoA) reductase is an enzyme that plays a crucial role in the synthesis of cholesterol in the body. It is found in the endoplasmic reticulum of cells and catalyzes the conversion of HMG-CoA to mevalonic acid, which is a key rate-limiting step in the cholesterol biosynthetic pathway.

The reaction catalyzed by HMG-CoA reductase is as follows:

HMG-CoA + 2 NADPH + 2 H+ → mevalonic acid + CoA + 2 NADP+

This enzyme is the target of statin drugs, which are commonly prescribed to lower cholesterol levels in the treatment of cardiovascular diseases. Statins work by inhibiting HMG-CoA reductase, thereby reducing the production of cholesterol in the body.

Ribonucleotide Reductases (RNRs) are enzymes that play a crucial role in DNA synthesis and repair. They catalyze the conversion of ribonucleotides to deoxyribonucleotides, which are the building blocks of DNA. This process involves the reduction of the 2'-hydroxyl group of the ribose sugar to a hydrogen, resulting in the formation of deoxyribose.

RNRs are highly regulated and exist in various forms across different species. They are divided into three classes (I, II, and III) based on their structure, mechanism, and cofactor requirements. Class I RNRs are further divided into two subclasses (Ia and Ib), which differ in their active site architecture and regulation.

Class Ia RNRs, found in eukaryotes and some bacteria, contain a stable tyrosyl radical that acts as the catalytic center for hydrogen abstraction. Class Ib RNRs, found in many bacteria, use a pair of iron centers to perform the same function. Class II RNRs are present in some bacteria and archaea and utilize adenosine triphosphate (ATP) as a cofactor for reduction. Class III RNRs, found in anaerobic bacteria and archaea, use a unique mechanism involving a radical S-adenosylmethionine (SAM) cofactor to facilitate the reduction reaction.

RNRs are essential for DNA replication and repair, and their dysregulation has been linked to various diseases, including cancer and neurodegenerative disorders. Therefore, understanding the structure, function, and regulation of RNRs is of great interest in biochemistry, molecular biology, and medicine.

Estradiol is a type of estrogen, which is a female sex hormone. It is the most potent and dominant form of estrogen in humans. Estradiol plays a crucial role in the development and maintenance of secondary sexual characteristics in women, such as breast development and regulation of the menstrual cycle. It also helps maintain bone density, protect the lining of the uterus, and is involved in cognition and mood regulation.

Estradiol is produced primarily by the ovaries, but it can also be synthesized in smaller amounts by the adrenal glands and fat cells. In men, estradiol is produced from testosterone through a process called aromatization. Abnormal levels of estradiol can contribute to various health issues, such as hormonal imbalances, infertility, osteoporosis, and certain types of cancer.

Nitrite reductases are a group of enzymes that catalyze the reduction of nitrite (NO2-) to nitric oxide (NO). This reaction is an important part of the nitrogen cycle, particularly in denitrification and dissimilatory nitrate reduction to ammonium (DNRA) processes. Nitrite reductases can be classified into two main types based on their metal co-factors: copper-containing nitrite reductases (CuNiRs) and cytochrome cd1 nitrite reductases. CuNiRs are typically found in bacteria and fungi, while cytochrome cd1 nitrite reductases are primarily found in bacteria. These enzymes play a crucial role in the global nitrogen cycle and have potential implications for environmental and medical research.

Glutathione reductase (GR) is an enzyme that plays a crucial role in maintaining the cellular redox state. The primary function of GR is to reduce oxidized glutathione (GSSG) to its reduced form (GSH), which is an essential intracellular antioxidant. This enzyme utilizes nicotinamide adenine dinucleotide phosphate (NADPH) as a reducing agent in the reaction, converting it to NADP+. The medical definition of Glutathione Reductase is:

Glutathione reductase (GSR; EC 1.8.1.7) is a homodimeric flavoprotein that catalyzes the reduction of oxidized glutathione (GSSG) to reduced glutathione (GSH) in the presence of NADPH as a cofactor. This enzyme is essential for maintaining the cellular redox balance and protecting cells from oxidative stress by regenerating the active form of glutathione, a vital antioxidant and detoxifying agent.

Flavin Mononucleotide (FMN) Reductase is an enzyme that catalyzes the reduction of FMN to FMNH2 using NADH or NADPH as an electron donor. This enzyme plays a crucial role in the electron transport chain and is involved in various redox reactions within the cell. It is found in many organisms, including bacteria, fungi, plants, and animals. In humans, FMN Reductase is encoded by the RIBFLR gene and is primarily located in the mitochondria. Defects in this enzyme can lead to various metabolic disorders.

Thioredoxin-disulfide reductase (Txnrd, TrxR) is an enzyme that belongs to the pyridine nucleotide-disulfide oxidoreductase family. It plays a crucial role in maintaining the intracellular redox balance by reducing disulfide bonds in proteins and keeping them in their reduced state. This enzyme utilizes NADPH as an electron donor to reduce thioredoxin (Trx), which then transfers its electrons to various target proteins, thereby regulating their activity, protein folding, and antioxidant defense mechanisms.

Txnrd is essential for several cellular processes, including DNA synthesis, gene expression, signal transduction, and protection against oxidative stress. Dysregulation of Txnrd has been implicated in various pathological conditions, such as cancer, neurodegenerative diseases, and inflammatory disorders. Therefore, understanding the function and regulation of this enzyme is of great interest for developing novel therapeutic strategies.

NADPH-ferrihemoprotein reductase, also known as diaphorase or NO synthase reductase, is an enzyme that catalyzes the reduction of ferrihemoproteins using NADPH as a reducing cofactor. This reaction plays a crucial role in various biological processes such as the detoxification of certain compounds and the regulation of cellular signaling pathways.

The systematic name for this enzyme is NADPH:ferrihemoprotein oxidoreductase, and it belongs to the family of oxidoreductases that use NADH or NADPH as electron donors. The reaction catalyzed by this enzyme can be represented as follows:

NADPH + H+ + ferrihemoprotein ↔ NADP+ + ferrohemoprotein

In this reaction, the ferric (FeIII) form of hemoproteins is reduced to its ferrous (FeII) form by accepting electrons from NADPH. This enzyme is widely distributed in various tissues and organisms, including bacteria, fungi, plants, and animals. It has been identified as a component of several multi-enzyme complexes involved in different metabolic pathways, such as nitric oxide synthase (NOS) and cytochrome P450 reductase.

In summary, NADPH-ferrihemoprotein reductase is an essential enzyme that catalyzes the reduction of ferrihemoproteins using NADPH as a reducing agent, playing a critical role in various biological processes and metabolic pathways.

Ferredoxin-NADP Reductase (FDNR) is an enzyme that catalyzes the electron transfer from ferredoxin to NADP+, reducing it to NADPH. This reaction plays a crucial role in several metabolic pathways, including photosynthesis and nitrogen fixation.

In photosynthesis, FDNR is located in the stroma of chloroplasts and receives electrons from ferredoxin, which is reduced by photosystem I. The enzyme then transfers these electrons to NADP+, generating NADPH, which is used in the Calvin cycle for carbon fixation.

In nitrogen fixation, FDNR is found in the nitrogen-fixing bacteria and receives electrons from ferredoxin, which is reduced by nitrogenase. The enzyme then transfers these electrons to NADP+, generating NADPH, which is used in the reduction of nitrogen gas (N2) to ammonia (NH3).

FDNR is a flavoprotein that contains a FAD cofactor and an iron-sulfur cluster. The enzyme catalyzes the electron transfer through a series of conformational changes that bring ferredoxin and NADP+ in close proximity, allowing for efficient electron transfer.

Oxidoreductases are a class of enzymes that catalyze oxidation-reduction reactions, which involve the transfer of electrons from one molecule (the reductant) to another (the oxidant). These enzymes play a crucial role in various biological processes, including energy production, metabolism, and detoxification.

The oxidoreductase-catalyzed reaction typically involves the donation of electrons from a reducing agent (donor) to an oxidizing agent (acceptor), often through the transfer of hydrogen atoms or hydride ions. The enzyme itself does not undergo any permanent chemical change during this process, but rather acts as a catalyst to lower the activation energy required for the reaction to occur.

Oxidoreductases are classified and named based on the type of electron donor or acceptor involved in the reaction. For example, oxidoreductases that act on the CH-OH group of donors are called dehydrogenases, while those that act on the aldehyde or ketone groups are called oxidases. Other examples include reductases, peroxidases, and catalases.

Understanding the function and regulation of oxidoreductases is important for understanding various physiological processes and developing therapeutic strategies for diseases associated with impaired redox homeostasis, such as cancer, neurodegenerative disorders, and cardiovascular disease.

The corpus luteum is a temporary endocrine structure that forms in the ovary after an oocyte (egg) has been released from a follicle during ovulation. It's formed by the remaining cells of the ruptured follicle, which transform into large, hormone-secreting cells.

The primary function of the corpus luteum is to produce progesterone and, to a lesser extent, estrogen during the menstrual cycle or pregnancy. Progesterone plays a crucial role in preparing the uterus for potential implantation of a fertilized egg and maintaining the early stages of pregnancy. If pregnancy does not occur, the corpus luteum will typically degenerate and stop producing hormones after approximately 10-14 days, leading to menstruation.

However, if pregnancy occurs, the developing embryo starts to produce human chorionic gonadotropin (hCG), which signals the corpus luteum to continue secreting progesterone and estrogen until the placenta takes over hormonal production, usually around the end of the first trimester.

Cytochrome reductases are a group of enzymes that play a crucial role in the electron transport chain, a process that occurs in the mitochondria of cells and is responsible for generating energy in the form of ATP (adenosine triphosphate). Specifically, cytochrome reductases are responsible for transferring electrons from one component of the electron transport chain to another, specifically to cytochromes.

There are several types of cytochrome reductases, including NADH dehydrogenase (also known as Complex I), succinate dehydrogenase (also known as Complex II), and ubiquinone-cytochrome c reductase (also known as Complex III). These enzymes help to facilitate the flow of electrons through the electron transport chain, which is essential for the production of ATP and the maintenance of cellular homeostasis.

Defects in cytochrome reductases can lead to a variety of mitochondrial diseases, which can affect multiple organ systems and may be associated with symptoms such as muscle weakness, developmental delays, and cardiac dysfunction.

Progesterone congeners refer to synthetic or naturally occurring compounds that are structurally similar to progesterone, a steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis. These compounds have similar chemical structures to progesterone and may exhibit similar physiological activities, although they can also have unique properties and uses. Examples of progesterone congeners include various synthetic progestins used in hormonal contraceptives and other medical treatments.

Mifepristone is a synthetic steroid that is used in the medical termination of pregnancy (also known as medication abortion or RU-486). It works by blocking the action of progesterone, a hormone necessary for maintaining pregnancy. Mifepristone is often used in combination with misoprostol to cause uterine contractions and expel the products of conception from the uterus.

It's also known as an antiprogestin or progesterone receptor modulator, which means it can bind to progesterone receptors in the body and block their activity. In addition to its use in pregnancy termination, mifepristone has been studied for its potential therapeutic uses in conditions such as Cushing's syndrome, endometriosis, uterine fibroids, and hormone-dependent cancers.

It is important to note that Mifepristone should be administered under the supervision of a licensed healthcare professional and it is not available over the counter. Also, it has some contraindications and potential side effects, so it's essential to have a consultation with a doctor before taking this medication.

Progestins are a class of steroid hormones that are similar to progesterone, a natural hormone produced by the ovaries during the menstrual cycle and pregnancy. They are often used in hormonal contraceptives, such as birth control pills, shots, and implants, to prevent ovulation and thicken the cervical mucus, making it more difficult for sperm to reach the egg. Progestins are also used in menopausal hormone therapy to alleviate symptoms of menopause, such as hot flashes and vaginal dryness. Additionally, progestins may be used to treat endometriosis, uterine fibroids, and breast cancer. Different types of progestins have varying properties and may be more suitable for certain indications or have different side effect profiles.

Estrus is a term used in veterinary medicine to describe the physiological and behavioral state of female mammals that are ready to mate and conceive. It refers to the period of time when the female's reproductive system is most receptive to fertilization.

During estrus, the female's ovaries release one or more mature eggs (ovulation) into the fallopian tubes, where they can be fertilized by sperm from a male. This phase of the estrous cycle is often accompanied by changes in behavior and physical appearance, such as increased vocalization, restlessness, and swelling of the genital area.

The duration and frequency of estrus vary widely among different species of mammals. In some animals, such as dogs and cats, estrus occurs regularly at intervals of several weeks or months, while in others, such as cows and mares, it may only occur once or twice a year.

It's important to note that the term "estrus" is not used to describe human reproductive physiology. In humans, the equivalent phase of the menstrual cycle is called ovulation.

Luteinizing Hormone (LH) is a glycoprotein hormone, which is primarily produced and released by the anterior pituitary gland. In women, a surge of LH triggers ovulation, the release of an egg from the ovaries during the menstrual cycle. During pregnancy, LH stimulates the corpus luteum to produce progesterone. In men, LH stimulates the testes to produce testosterone. It plays a crucial role in sexual development, reproduction, and maintaining the reproductive system.

Tetrahydrofolate dehydrogenase (EC 1.5.1.20) is an enzyme involved in folate metabolism. The enzyme catalyzes the oxidation of tetrahydrofolate (THF) to dihydrofolate (DHF), while simultaneously reducing NADP+ to NADPH.

The reaction can be summarized as follows:

THF + NADP+ -> DHF + NADPH + H+

This enzyme plays a crucial role in the synthesis of purines and thymidylate, which are essential components of DNA and RNA. Therefore, any defects or deficiencies in tetrahydrofolate dehydrogenase can lead to various medical conditions, including megaloblastic anemia and neural tube defects during fetal development.

Pregnancy is a physiological state or condition where a fertilized egg (zygote) successfully implants and grows in the uterus of a woman, leading to the development of an embryo and finally a fetus. This process typically spans approximately 40 weeks, divided into three trimesters, and culminates in childbirth. Throughout this period, numerous hormonal and physical changes occur to support the growing offspring, including uterine enlargement, breast development, and various maternal adaptations to ensure the fetus's optimal growth and well-being.

The uterus, also known as the womb, is a hollow, muscular organ located in the female pelvic cavity, between the bladder and the rectum. It has a thick, middle layer called the myometrium, which is composed of smooth muscle tissue, and an inner lining called the endometrium, which provides a nurturing environment for the fertilized egg to develop into a fetus during pregnancy.

The uterus is where the baby grows and develops until it is ready for birth through the cervix, which is the lower, narrow part of the uterus that opens into the vagina. The uterus plays a critical role in the menstrual cycle as well, by shedding its lining each month if pregnancy does not occur.

Ovariectomy is a surgical procedure in which one or both ovaries are removed. It is also known as "ovary removal" or "oophorectomy." This procedure is often performed as a treatment for various medical conditions, including ovarian cancer, endometriosis, uterine fibroids, and pelvic pain. Ovariectomy can also be part of a larger surgical procedure called an hysterectomy, in which the uterus is also removed.

In some cases, an ovariectomy may be performed as a preventative measure for individuals at high risk of developing ovarian cancer. This is known as a prophylactic ovariectomy. After an ovariectomy, a person will no longer have menstrual periods and will be unable to become pregnant naturally. Hormone replacement therapy may be recommended in some cases to help manage symptoms associated with the loss of hormones produced by the ovaries.

The luteal phase is the second half of the menstrual cycle, starting from ovulation (release of an egg from the ovaries) and lasting until the start of the next menstruation. This phase typically lasts around 12-14 days in a regular 28-day menstrual cycle. During this phase, the remains of the dominant follicle that released the egg transform into the corpus luteum, which produces progesterone and some estrogen to support the implantation of a fertilized egg and maintain the early stages of pregnancy. If pregnancy does not occur, the corpus luteum degenerates, leading to a drop in hormone levels and the start of a new menstrual cycle.

An ovary is a part of the female reproductive system in which ova or eggs are produced through the process of oogenesis. They are a pair of solid, almond-shaped structures located one on each side of the uterus within the pelvic cavity. Each ovary measures about 3 to 5 centimeters in length and weighs around 14 grams.

The ovaries have two main functions: endocrine (hormonal) function and reproductive function. They produce and release eggs (ovulation) responsible for potential fertilization and development of an embryo/fetus during pregnancy. Additionally, they are essential in the production of female sex hormones, primarily estrogen and progesterone, which regulate menstrual cycles, sexual development, and reproduction.

During each menstrual cycle, a mature egg is released from one of the ovaries into the fallopian tube, where it may be fertilized by sperm. If not fertilized, the egg, along with the uterine lining, will be shed, leading to menstruation.

"Animal pregnancy" is not a term that is typically used in medical definitions. However, in biological terms, animal pregnancy refers to the condition where a fertilized egg (or eggs) implants and develops inside the reproductive tract of a female animal, leading to the birth of offspring (live young).

The specific details of animal pregnancy can vary widely between different species, with some animals exhibiting phenomena such as placental development, gestation periods, and hormonal changes that are similar to human pregnancy, while others may have very different reproductive strategies.

It's worth noting that the study of animal pregnancy and reproduction is an important area of biological research, as it can provide insights into fundamental mechanisms of embryonic development, genetics, and evolution.

Ovulation is the medical term for the release of a mature egg from an ovary during a woman's menstrual cycle. The released egg travels through the fallopian tube where it may be fertilized by sperm if sexual intercourse has occurred recently. If the egg is not fertilized, it will break down and leave the body along with the uterine lining during menstruation. Ovulation typically occurs around day 14 of a 28-day menstrual cycle, but the timing can vary widely from woman to woman and even from cycle to cycle in the same woman.

During ovulation, there are several physical changes that may occur in a woman's body, such as an increase in basal body temperature, changes in cervical mucus, and mild cramping or discomfort on one side of the lower abdomen (known as mittelschmerz). These symptoms can be used to help predict ovulation and improve the chances of conception.

It's worth noting that some medical conditions, such as polycystic ovary syndrome (PCOS) or premature ovarian failure, may affect ovulation and make it difficult for a woman to become pregnant. In these cases, medical intervention may be necessary to help promote ovulation and increase the chances of conception.

The endometrium is the innermost layer of the uterus, which lines the uterine cavity and has a critical role in the menstrual cycle and pregnancy. It is composed of glands and blood vessels that undergo cyclic changes under the influence of hormones, primarily estrogen and progesterone. During the menstrual cycle, the endometrium thickens in preparation for a potential pregnancy. If fertilization does not occur, it will break down and be shed, resulting in menstruation. In contrast, if implantation takes place, the endometrium provides essential nutrients to support the developing embryo and placenta throughout pregnancy.

Estrogen receptors (ERs) are a type of nuclear receptor protein that are expressed in various tissues and cells throughout the body. They play a critical role in the regulation of gene expression and cellular responses to the hormone estrogen. There are two main subtypes of ERs, ERα and ERβ, which have distinct molecular structures, expression patterns, and functions.

ERs function as transcription factors that bind to specific DNA sequences called estrogen response elements (EREs) in the promoter regions of target genes. When estrogen binds to the ER, it causes a conformational change in the receptor that allows it to recruit co-activator proteins and initiate transcription of the target gene. This process can lead to a variety of cellular responses, including changes in cell growth, differentiation, and metabolism.

Estrogen receptors are involved in a wide range of physiological processes, including the development and maintenance of female reproductive tissues, bone homeostasis, cardiovascular function, and cognitive function. They have also been implicated in various pathological conditions, such as breast cancer, endometrial cancer, and osteoporosis. As a result, ERs are an important target for therapeutic interventions in these diseases.

NADP (Nicotinamide Adenine Dinucleotide Phosphate) is a coenzyme that plays a crucial role as an electron carrier in various redox reactions in the human body. It exists in two forms: NADP+, which functions as an oxidizing agent and accepts electrons, and NADPH, which serves as a reducing agent and donates electrons.

NADPH is particularly important in anabolic processes, such as lipid and nucleotide synthesis, where it provides the necessary reducing equivalents to drive these reactions forward. It also plays a critical role in maintaining the cellular redox balance by participating in antioxidant defense mechanisms that neutralize harmful reactive oxygen species (ROS).

In addition, NADP is involved in various metabolic pathways, including the pentose phosphate pathway and the Calvin cycle in photosynthesis. Overall, NADP and its reduced form, NADPH, are essential molecules for maintaining proper cellular function and energy homeostasis.

Methionine sulfoxide reductases (MSRs) are a group of enzymes that catalyze the reduction of methionine sulfoxides back to methionine in proteins. Methionine residues in proteins can be oxidized by reactive oxygen species (ROS) or other oxidizing agents, leading to the formation of methionine sulfoxide. This modification can affect protein function and stability. MSRs play a crucial role in protecting proteins from oxidative damage and maintaining their proper function.

There are two types of MSRs, designated as MSRA and MSRB. MSRA reduces methionine-S-sulfoxides, while MSRB reduces methionine-R-sulfoxides. Both enzymes require the cofactor thioredoxin to reduce the methionine sulfoxide back to methionine. The activity of MSRs is important in various biological processes, including protein folding, stress response, and aging. Defects in MSRs have been implicated in several diseases, such as Alzheimer's disease, Parkinson's disease, and cancer.

Hormone antagonists are substances or drugs that block the action of hormones by binding to their receptors without activating them, thereby preventing the hormones from exerting their effects. They can be classified into two types: receptor antagonists and enzyme inhibitors. Receptor antagonists bind directly to hormone receptors and prevent the hormone from binding, while enzyme inhibitors block the production or breakdown of hormones by inhibiting specific enzymes involved in their metabolism. Hormone antagonists are used in the treatment of various medical conditions, such as cancer, hormonal disorders, and cardiovascular diseases.

Other names in common use include steroid 5-alpha-reductase, and Delta4-steroid 5alpha-reductase (progesterone). Cheng YJ, ... In enzymology, a progesterone 5alpha-reductase (EC 1.3.1.22) is an enzyme that catalyzes the chemical reaction 5alpha-pregnan-3 ... Cheng YJ, Karavolas HJ (1975). "Properties and subcellular distribution of delta4-steroid (progesterone) 5alpha-reductase in ... Karavolas HJ (1975). "Subcellular distribution and properties of progesterone (delta4-steroid) 5alpha-reductase in rat medial ...
It is synthesized from progesterone by the enzyme 5β-reductase. 5β-DHP has been found to act as a positive allosteric modulator ... A study found that 5β-DHP, but not progesterone, directly bound to and antagonized the oxytocin receptor at nanomolar ... Unlike 5α-dihydroprogesterone, 5β-DHP possesses only very weak affinity for the progesterone receptor (1.2% of that of ... Illingworth DV, Elsner C, De Groot K, Flickinger GL, Mikhail G (February 1977). "A specific progesterone receptor of myometrial ...
Progesterone 5β-reductase, which was initially proposed as an enzyme of cardenolide biosynthesis in Digitalis, also has been ... Expression of two progesterone 5β-reductase and three 3β-hydroxysteroid dehydrogenase genes was detected in shoot cultures. ... Munkert, Jennifer; Bauer, Peter; Burda, Edyta; Müller-Uri, Frieder; Kreis, Wolfgang (2011). "Progesterone 5β-reductase of ...
Both the pregnane and norcholanic acid pathways use progesterone 5β-reductases, the P5βR and P5βR2 respectively. In the ... "Highly conserved progesterone 5β-reductase genes (P5βR) from 5β-cardenolide-free and 5β-cardenolide-producing angiosperms". ... is thought to catalyze the conversion of pregnenolone to progesterone. Progesterone is further processed by P5βR to 5β-Pregnane ...
In addition, similarly to progesterone, medrogestone can inhibit 5α-reductase in vitro in microsomal preparations of skin and ... Medrogestone is described as a pure progestogen similar in profile to progesterone. In contrast to progesterone however, ... Medrogestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological ... 94-. ISBN 978-93-5090-958-4. The natural preparations of P4 include progesterone, dydrogesterone, and medrogestone. Carter WF, ...
Munkert, Jennifer; Bauer, Peter; Burda, Edyta; Müller-Uri, Frieder; Kreis, Wolfgang (2011). "Progesterone 5β-reductase of ...
... of sterol biosynthesis and of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in cultured cells by progesterone". The ... Peffley DM, Gayen AK, Morand OH (Aug 1998). "Down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels and ... is believed to be responsible for this inhibition of HMG-CoA reductase activity. It is believed that oxidosqualene cyclases ( ... which is more closely tied to cholesterol biosynthesis than HMG-CoA reductase, is an attractive drug target. Lanosterol ...
... has been reported to act to some extent as a 5α-reductase inhibitor, similarly to progesterone. Like the ... As progesterone is metabolized mainly into 5β-pregnanes, decreased 5β-reduction of gestonorone caproate may be involved in its ... Gestonorone caproate is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the ... It is approximately 20 to 25 times more potent than progesterone or hydroxyprogesterone caproate in animal bioassays when all ...
... of allopregnanolone in the brain starts with the conversion of progesterone into 5α-dihydroprogesterone by 5α-reductase. After ... Exogenous progesterone, such as oral progesterone, elevates allopregnanolone levels in the body with good dose-to-serum level ... Unlike progesterone, allopregnanolone is inactive at the classical nuclear progesterone receptor (PR). However, ... Also like progesterone, recent evidence has shown that allopregnanolone is an activator of the pregnane X receptor. Similarly ...
... is synthesized from progesterone via the enzymes 5β-reductase and 3α-hydroxysteroid dehydrogenase, with 5β- ... is an endogenous inhibitory neurosteroid which is produced in the body from progesterone. It is closely related to ... is a naturally occurring pregnane steroid and a derivative of progesterone. Related compounds include allopregnanolone (3α,5α- ...
Other names in common use include: progesterone reductase Δ5-3β-hydroxysteroid dehydrogenase 3β-hydroxy-5-ene steroid ... The 3β-HSD complex is responsible for the conversion of: Pregnenolone to progesterone 17α-Hydroxypregnenolone to 17α- ... Its importance in placental progesterone production expression suggests that such a mutation would be embryonically lethal. The ... Koritz SB (1964). "The conversion of prepnenolone to progesterone by small particle from rat adrenal". Biochemistry. 3 (8): ...
... progesterone 5alpha-reductase - promoter - pronucleus - prostate cancer - protease - proteasome - proteasome ATPase - protein ... diethyl 2-methyl-3-oxosuccinate reductase - dihydrochelirubine 12-monooxygenase - dimethyl sulfide:cytochrome c2 reductase - ... reductase (NADH) - (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase - 3(or 17)a-hydroxysteroid dehydrogenase - 3110001I22Rik - ... plastoquinol/plastocyanin reductase - point mutation - poly-A track - polyA tail - polyacrylamide gel - polyclonal antibodies ...
The following reactions are known to be catalyzed by 5α-reductase: Cholestenone → 5α-Cholestanone Progesterone → 5α- ... There are three isoenzymes of 5α-reductase: steroid 5α-reductase 1, 2, and 3 (SRD5A1, SRD5A2 and SRD5A3). 5α-Reductases act on ... Impaired 5α-reductase 2 activity can result from mutations in the underlying SRD5A2 gene. The condition, known as 5α-reductase ... Beyond reducing testosterone to dihydrotestosterone, 5alpha-reductase enzyme isoforms I and II reduce progesterone to ...
Although systemic progesterone does not appear to be an effective 5α-reductase inhibitor, topical progesterone may produce ... A progesterone vaginal ring and progesterone intrauterine device are also available as pharmaceutical products. Progesterone is ... A study of a vaginal progesterone ring that released almost 10 mg/day progesterone and maintained mean progesterone levels of ... In another study, a progesterone vaginal ring that released about 10 mg/day progesterone and produced progesterone levels of ...
incubated the testes of tammar wallaby pouch young with radiolabelled progesterone to show that 5α-reductase expression in this ... The pathway from progesterone (P4) to DHT is similar to that described above from 17-OHP to DHT, but the initial substrate for ... Mahendroo, Mala; Wilson, Jean D.; Richardson, James A.; Auchus, Richard J. (2004). "Steroid 5alpha-reductase 1 promotes 5alpha- ... "High serum progesterone associated with infertility in a woman with nonclassic congenital adrenal hyperplasia". J Obstet ...
... is biosynthesized from progesterone by the actions of 5β-reductase and 3β-hydroxysteroid dehydrogenase, with 5β ...
5α-reductase isoforms I and II reduce progesterone to 5α-dihydroprogesterone (5α-DHP) and deoxycorticosterone to ... List of 5α-reductase inhibitors Discovery and development of 5α-reductase inhibitors CYP17A1 inhibitor Neurosteroidogenesis ... The 5α-reductase reaction is a rate-limiting step in the testosterone reduction and involves the binding of NADPH to the enzyme ... 5α-Reductase reduces the steroid Δ4,5 double bond in testosterone to its more active form DHT. Thus, inhibition results in ...
5β-Reductase is also a major enzyme in the metabolism of progesterone. 5α-Reduction of progesterone occurs predominantly in the ... The metabolites of progesterone produced by 5α-reductase and 5β-reductase (after further transformation by 3α-hydroxysteroid ... A progesterone vaginal ring and progesterone intrauterine device are also available as pharmaceutical products. Progesterone is ... metabolize progesterone in the skin. Progesterone and/or its metabolites such as 5α-dihydroprogesterone act as 5α-reductase ...
The major metabolic pathway of progesterone is reduction by 5α-reductase and 5β-reductase into the dihydrogenated 5α- ... Progesterone is highly susceptible to enzymatic reduction via reductases and hydroxysteroid dehydrogenases due to its double ... Since eggs release progesterone, sperm may use progesterone as a homing signal to swim toward eggs (chemotaxis). As a result, ... Progesterone can be taken by mouth, through the vagina, and by injection into muscle or fat, among other routes. Progesterone ...
... experimental characterization results suggested that morphinone reductase activity is competitively inhibited by progesterone ... Morphinone reductase is a dimeric flavoenzyme comprising two 8-fold α/β-barrel domains, each with a non-covalently bound FMN ... Morphinone reductase is an enzyme which catalyzes the NADH-dependent saturation of the carbon-carbon double bond of morphinone ... Morphinone reductase was also successfully expressed in these two organisms. The enzyme represents a promising candidate for ...
It is synthesized from the adrenal hormone deoxycorticosterone (DOC) by the enzyme 5α-reductase type I. DHDOC is an agonist of ... the progesterone receptor, as well as a positive allosteric modulator of the GABAA receptor, and is known to have ...
Progesterone is metabolized by 5α- and 5β-reductases, 3α- and 3β-hydroxysteroid dehydrogenases, and 20α- and 20β-hydroxysteroid ... Due to its much longer duration than parenteral progesterone, hydroxyprogesterone caproate had largely replaced progesterone in ... "Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors". ... "Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha ...
5α-Reductase inhibitors such as finasteride and dutasteride inhibit the conversion of progesterone into the inhibitory ... The progesterone ethers quingestrone (progesterone 3-cyclopentyl enol ether) and progesterone 3-acetyl enol ether are among the ... Sublingual progesterone tablets were marketed under the brand names Progesterone Lingusorbs and Progesterone Membrettes by 1951 ... In contrast to oral progesterone, non-oral progesterone-which can achieve much higher progesterone levels-has not been assessed ...
This is thought to be due to prevention by 5α-reductase inhibitors of the conversion of progesterone into allopregnanolone ... 5α-Reductase inhibitors are inhibitors of the enzyme 5α-reductase, and are a type of specific androgen synthesis inhibitor. 5α- ... 5α-Reductase inhibitors include finasteride and dutasteride. Finasteride is a selective inhibitor of 5α-reductase types 2 and 3 ... progesterone were given. These injections were continued for another month, increasing progesterone to 100 mg. daily. Both ...
"The enantiomer of progesterone (ent-progesterone) is a competitive inhibitor of human cytochromes P450c17 and P450c21". ... Loss of scalp hair in females and males is embarrassing, requiring treatment with 5α-reductase inhibitors Feingold KR, Anawalt ... The catalytic efficiency of 21-hydroxylase for conversion of progesterone in humans is approximately 1.3 x 107 M−1s−1 at 37 °C ... The chemical reaction in which 21-hydroxylase catalyzes the addition of hydroxyl (-OH) to the C21 position of progesterone, 17α ...
The steroid has been found to possess 82% of the affinity of progesterone for the progesterone receptor in rhesus monkey uterus ... 5α-DHP is metabolized by the aldo-keto reductases (AKRs) AKR1C1, AKR1C2, and AKR1C4 with high catalytic efficiency. AKR1C1 ... 5α-DHP is an agonist of the progesterone receptor and a positive allosteric modulator of the GABAA receptor (albeit with an ... September 1993). "Progesterone receptor-mediated effects of neuroactive steroids". Neuron. 11 (3): 523-30. doi:10.1016/0896- ...
H+ The human enzyme efficiently acts on progesterone, 17α-hydroxyprogesterone, androstenedione, and testosterone to 5β-reduced ... cholestenone 5β-reductase, cortisone 5β-reductase, cortisone Δ4-5β-reductase, steroid 5β-reductase, testosterone 5β-reductase, ... 5β-Reductase, or Δ4-3-oxosteroid 5β-reductase (EC 1.3.1.3, 3-oxo-Δ4-steroid 5β-reductase, androstenedione 5β-reductase, ... Δ4-3-ketosteroid 5β-reductase, Δ4-5β-reductase, Δ4-hydrogenase, 4,5β-dihydrocortisone:NADP+ Δ4-oxidoreductase, 3-oxo-5β-steroid ...
Males with congenital 5α-reductase type 2 deficiency (but functional 5α-reductase type 1) never develop male-pattern hair loss ... suppress estrogen and progesterone levels, and prevent/reverse feminization; GnRH agonists and antagonists to suppress estrogen ... and progesterone levels; progestins like medroxyprogesterone acetate to suppress menses; and 5α-reductase inhibitors to prevent ... Testosterone is converted (within the cells of the hair follicle's dermal papilla) by 5α-reductase to DHT. There are two forms ...
... bind to cytochrome P450 reductase and alter its conformation as well as activity towards supporting metabolism of progesterone ...
... is synthesized from progesterone in the body by the actions of the enzymes 5α-reductase and 3β-hydroxysteroid ... Levels of isopregnanolone, progesterone, and allopregnanolone are highly correlated across the menstrual cycle and throughout ... The concentrations of isopregnanolone are significantly less than those of progesterone and allopregnanolone; about half of ... The progesterone metabolite isoallopregnanolone is a subunit-selective antagonist of the GABA-A receptor. Chicago Bäckström T, ...
Other names in common use include steroid 5-alpha-reductase, and Delta4-steroid 5alpha-reductase (progesterone). Cheng YJ, ... In enzymology, a progesterone 5alpha-reductase (EC 1.3.1.22) is an enzyme that catalyzes the chemical reaction 5alpha-pregnan-3 ... Cheng YJ, Karavolas HJ (1975). "Properties and subcellular distribution of delta4-steroid (progesterone) 5alpha-reductase in ... Karavolas HJ (1975). "Subcellular distribution and properties of progesterone (delta4-steroid) 5alpha-reductase in rat medial ...
PRP administered with progesterone inhibits 5-alpha reductase, preventing the conversion of testosterone to dihydrotestosterone ... Progesterone inhibits 5-alpha reductase and DHT, allowing hair growth to recover.. ... PRP injections with progesterone. PRP administered every 4 weeks for 24 weeks, then every 8-12 weeks indefinitely. ...
Progesterone Reductase/genetics; RNA, Messenger/metabolism; Silver/pharmacokinetics; Silver/toxicity*; Steroid Isomerases/ ...
Progesterone and its metabolite allopregnanolone (ALLO) have been found in animals to antagonize the effects of dopamine. We ... Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy. Zeng CM, Chang LL, Ying MD ... related to progesterone or DHEAS concentration. Serum DHEAS and progesterone concentrations were lower in men who had shown ... Progesterone and its metabolite allopregnanolone (ALLO) have been found in animals to antagonize the effects of dopamine. We ...
New progesterone esters as 5alpha-reductase inhibitors.. Cabeza M; Heuze I; Bratoeff E; Murillo E; Ramirez E; Lira A. Chem ... Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors.. Bratoeff E; Segura T; Recillas S; ... 4. New 5alpha-reductase inhibitors: in vitro and in vivo effects.. Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; ... 2. Steroid 5alpha-reductase inhibitors.. Flores E; Bratoeff E; Cabeza M; Ramirez E; Quiroz A; Heuze I. Mini Rev Med Chem; 2003 ...
New progesterone esters as 5alpha-reductase inhibitors.. Cabeza M; Heuze I; Bratoeff E; Murillo E; Ramirez E; Lira A. Chem ... Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors.. Bratoeff E; Segura T; Recillas S; ... 6. New 5alpha-reductase inhibitors: in vitro and in vivo effects.. Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; ... 3. Steroid 5alpha-reductase inhibitors.. Flores E; Bratoeff E; Cabeza M; Ramirez E; Quiroz A; Heuze I. Mini Rev Med Chem; 2003 ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
Progesterone reductase Current Synonym true false Associated Value Sets No associated value sets.. ...
Progesterone Reductase Preferred Term Term UI T033554. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1975). ... Progesterone Reductase Preferred Concept UI. M0017673. Registry Number. EC 1.1.1.145. Scope Note. An enzyme that catalyzes the ... Progesterone Reductase. Tree Number(s). D08.811.682.047.436.350.700. D08.811.682.047.820.500. Unique ID. D011375. RDF Unique ... It converts pregnenolone to progesterone and dehydroepiandrosterone to androstenedione. EC 1.1.1.145.. Entry Term(s). 3 beta- ...
Progesterone Reductase Preferred Term Term UI T033554. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1975). ... Progesterone Reductase Preferred Concept UI. M0017673. Registry Number. EC 1.1.1.145. Scope Note. An enzyme that catalyzes the ... Progesterone Reductase. Tree Number(s). D08.811.682.047.436.350.700. D08.811.682.047.820.500. Unique ID. D011375. RDF Unique ... It converts pregnenolone to progesterone and dehydroepiandrosterone to androstenedione. EC 1.1.1.145.. Entry Term(s). 3 beta- ...
17. Faggionato E, Schiavon M, Dalla Man C. Knockout of Arabidopsis thaliana VEP1, encoding a PRISE (progesterone 5β-reductase/ ...
Progesterone Reductase - Preferred Concept UI. M0017673. Scope note. An enzyme that catalyzes the reduction of a 3 beta-hydroxy ... Progesterone Reductase Entry term(s). 3 beta Hydroxy delta 5 Steroid Dehydrogenase 3 beta-Hydroxy-delta-5-Steroid Dehydrogenase ... Progesterone reductase Entry term(s):. 3 beta Hydroxy delta 5 Steroid Dehydrogenase. 3 beta-Hydroxy-delta-5-Steroid ... Reductase, Progesterone. Steroid delta(5)-3 beta-ol Dehydrogenase. Tree number(s):. D08.811.682.047.436.350.700. D08.811. ...
progesterone 5-alpha-reductase activity. IEP. Neighborhood. BP. GO:0052314. phytoalexin metabolic process. IEP. Neighborhood. ...
progesterone 5-alpha-reductase activity GO:0050213 * glutamate synthase activity GO:0045181 ...
Progesterone 5-beta-reductase n=1 Tax=Nerium oleander RepID=D6N9X0_NEROL - - 0.0. 60% ...
N0000005934 Progesterone N0000011301 Progesterone Congeners N0000167986 Progesterone Reductase N0000169391 Progesterone-Binding ... N0000169057 Nitrate Reductase (NADH) N0000169643 Nitrate Reductase (NADPH) N0000167939 Nitrate Reductases N0000007647 Nitrates ... h N0000178702 Thioredoxin Reductase 1 N0000178714 Thioredoxin Reductase 2 N0000169063 Thioredoxin-Disulfide Reductase ... Reductase (NADPH, B-Specific) N0000167924 Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) N0000168032 Enoyl-CoA Hydratase ...
Produced from the conversion of Progesterone by the enzyme 5alpha-reductase , Allopregnanolone is a tranquilizer found in the ... As finasteride inhibits the conversion of progesterone to allopregnanolone by blocking the enzyme 5-alpha reductase, a higher ... d) Epigenetics: possible epigenetic changes in the 5-alpha reductase enzyme or ADN methylation are a source of investigation in ... level of progesterone is also possible in these patients.. Other tests:. Vitamin-D:. Many PFS patients have low levels of ...
The enzymatic conversion of progesterone and testosterone by the enzyme 5alpha-reductase exerts a crucial role in the control ... T increased AVP expression in SH-SY5Y cells by a mechanism that was dependent on aromatase but not on 5α-reductase activity. ... Kisspeptin system in ovariectomized mice: Estradiol and progesterone regulation. Marraudino, Marilena; Martini, Mariangela; ... Synergic effects of estradiol and progesterone on regulation of the hypothalamic neuronal nitric oxide synthase expression in ...
Progesterone does so much for you health! Beyond fertility and pregnancy, it has major implications for your body as a whole. ... Progesterone inhibits the 5-alpha reductase enzymes, and the result is clearer skin, less oil, and faster growing hair. ... The Powers Of Progesterone!. Progesterone stimulates the thyroid. This is why your temperature increases after ovulation, ... Progesterone aids in relaxation and enhances your sleep. A metabolite of progesterone directly interacts with the GABA ...
Clinical evaluation of potent dual 5alpha-reductase inhibitors may help define the relative roles of human type 1 and 2 5alpha- ... reductase in the pathophysiology of benign prostatic hyperplasia and other androgen-dependent diseases. ... Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk. Li W, Klein ... Type2 5alpha-reductase is the dominant isoenzyme in genital tissues, including the prostate. Finasteride is a 5alpha-reductase ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
Relations Profilins Proflavine Progeria Progesterone Progesterone Congeners Progesterone Reductase Progesterone-Binding ... Nitrate Reductase (NADH) Nitrate Reductase (NADPH) Nitrate Reductases Nitrates Nitrazepam Nitrendipine Nitrergic Neurons Nitric ... Thiopental Thiophanate Thiophenes Thioredoxin h Thioredoxin Reductase 1 Thioredoxin Reductase 2 Thioredoxin-Disulfide Reductase ... Hydroxymethylglutaryl CoA Reductases Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl-CoA Reductases, NAD- ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
K1.559.411.768 Progesterone Reductase D8.811.682.47.820.500 Propranolol D2.33.100.624.836 D2.33.755.624.836 Psychoses, ... E2.831.200 Cortisone Reductase D8.811.682.47.436.400.150 D8.811.682.47.820.125.150 Coxa Valga C5.550.338 Coxa Vara C5.550.353 ... C25.775.100.250 Aldehyde Reductase D8.811.682.47.820.275 Alexander Disease C10.228.518.625.312 alpha-2-Antiplasmin D12.776. ... D27.505.954.329.30.500 D-Xylulose Reductase D8.811.682.47.820.800 Dementia, Vascular C10.228.518.500 Demyelinating Autoimmune ...
HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, lovastatin, simvastatin. Opioids: alfentanil, fentanyl, sufentanil. ... Hormone replacement: cortisol, estradiol, methylprednisolone, progesterone, testosterone. Immunosuppressants: cyclosporine, ...
  • In enzymology, a progesterone 5alpha-reductase (EC 1.3.1.22) is an enzyme that catalyzes the chemical reaction 5alpha-pregnan-3,20-dione + NADP+ ⇌ {\displaystyle \rightleftharpoons } progesterone + NADPH + H+ Thus, the two substrates of this enzyme are 5alpha-pregnan-3,20-dione and NADP+, whereas its 3 products are progesterone, NADPH, and H+. (wikipedia.org)
  • Other names in common use include steroid 5-alpha-reductase, and Delta4-steroid 5alpha-reductase (progesterone). (wikipedia.org)
  • The neuroactive progestogen allopregnanolone (also known as 3,5-tetrahydroprogesterone or 3-hydroxy-5-pregnan-20-one) is synthesized from progesterone by isozymes on the enzyme 5alpha-reductase (5-reductase) and by the enzyme 3alpha-hydroxysteroid dehydrogenase (3-HSD). (deubiquitinaseinhibitor.com)
  • 5-alpha-reductase inhibitors Biotin Finasteride Progesterone Cream Anastrazole and 2 more. (infopathy.com)
  • Cyproterone acetate, Aldactone/spironolactone, 5-alpha-reductase inhibitors, phenytoin) within the last 6 months. (who.int)
  • The 5α-reductase inhibitor finasteride blocks the formation of ALLO from progesterone and was recently found to reduce certain effects of EtOH. (elsevierpure.com)
  • Typically, doctors may prescribe the drug terazosin (Hytrin) to relax urinary sphincter muscles, or the drug finasteride (Proscar) which inhibits the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT, a compound believed to stimulate prostate cell growth, or hyperplasia). (cellbone.com)
  • Natural alternatives such as saw palmetto berry and nettle root similarly inhibit 5-alpha reductase, and are just as effective as finasteride. (cellbone.com)
  • Progesterone, like finasteride and saw palmetto berry, inhibits 5-alpha reductase, and in turn, inhibits the conversion of testosterone to DHT. (cellbone.com)
  • In your menstrual cycle, progesterone rises after ovulation. (coconutsandkettlebells.com)
  • Progesterone is produced by the corpus luteum following ovulation and to a lesser extent by the adrenal glands in both sexes. (healthmatters.io)
  • The most important progesterone metabolite, pregnanediol (PDL), can serve as a urinary marker for endogenous progesterone levels and as an indicator of ovulation. (healthmatters.io)
  • That's why your body temperature goes up half a degree when you make progesterone after ovulation. (larabriden.com)
  • Quantitative trait loci (QTL) for age of puberty, nipple number and ovulation rate have been identified in Meishan crosses on pig chromosome 10q (SSC10) near the telomere, which is homologous to human chromosome 10p15 and contains an aldo-keto reductase (AKR) gene cluster with at least six family members. (biomedcentral.com)
  • Ample ascorbic acid levels are stimulatory to the hormones progesterone and oxytocin, and have been found in high concentrations in the corpus luteum of the ovary which makes progesterone after ovulation. (doctorherdmanclinic.com)
  • Aldo-keto reductases interconvert weak androgens, estrogens, progestins, mineralocorticoids and glucocorticoids to their more potent counterparts by catalyzing the reduction and oxidation of keto- and hydroxysteroids, respectively, thereby regulating a wide range of physiological processes involved in development, homeostasis and reproduction [ 16 ]. (biomedcentral.com)
  • Also, there was no significant difference in the gene expression of AKR1C (1-3) enzymes in the breast adipose tissues of patients with breast tumours, regardless of the oestrogen or progesterone receptor status. (manchester.ac.uk)
  • In the breast adipose tissue, there was also no significant difference in the gene expression of EP1-4 and FP receptors in patients with breast cancer regardless of the oestrogen or progesterone receptor status.The inhibitory constant (Ki) of bimatoprost was determined using oestrone as a substrate: Ki = 2.9µM and alphaKi = 0.7µM. (manchester.ac.uk)
  • Progesterone resistance due to suppressed progesterone receptor (PGR) expression and action is a general feature of endometriosis and is a cause of endometriosis-associated chronic pelvic pain, infertility, inflammatory disorders, and cancer. (emjreviews.com)
  • It appears that progesterone receptor polymorphisms may not be associated with the susceptibility to endometriosis. (emjreviews.com)
  • Nisolle and Donnez 4 speculated that inadequate secretory maturation in the endometriosis might cause from the reduction in progesterone receptor (PGR). (emjreviews.com)
  • Repurposing drugs used to treat various endocrine conditions were found to be neuroprotective such as estrogen, progesterone, the selective estrogen receptor modulator raloxifene, and the 5 α -reductase inhibitor, dutasteride. (ulaval.ca)
  • This component is a solid progesterone receptor or pregestogen. (1bpshop.com)
  • Acne in part can occur when high androgen levels such as testosterone get turned into its more potent form called dihydrotestosterone or DHT, via the action of an enzyme called 5-alpha reductase. (integrativeaestheticsboston.com)
  • In patients with 5-alpha-reductase deficiency who are raised as male, testosterone or dihydrotestosterone (DHT) therapy may increase penile length. (medscape.com)
  • The adrenal glands and testes in males produce progesterone. (aucklandskinclinic.co.nz)
  • Progesterone is a steroid hormone primarily synthesised by the ovaries and adrenal glands, and also by the placenta during pregnancy. (emjreviews.com)
  • The adrenal glands are responsible for how your body provides this powerful progesterone if/when you are not ovulating and particularly through perimenopause or the menopausal transition. (heyfreya.co)
  • Adrenal health is progesterone health and therefore is women's health. (heyfreya.co)
  • An adrenal microsomal cytochrome P450 enzyme that catalyzes the 21-hydroxylation of steroids in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. (lookformedical.com)
  • I did not want another health issue to deal with in addition to my juvenile diabetes, Hashi's , adrenal fatigue , very low iron , Poly-Cystic Ovarian Syndrome and endometriosis with low progesterone, estrogen and testosterone. (stopthethyroidmadness.com)
  • In conditions where androgen response or synthesis leads to a DSD, such as partial androgen insensitivity syndrome (PAIS), 17-beta-hydroxysteroid dehydrogenase deficiency, and 5-alpha-reductase deficiency (5-ARD), attaining all of these goals is likely impossible. (medscape.com)
  • In select cultures with high prevalence of 5-alpha-reductase deficiency, such as the Dominican Republic and Papua New-Guinea, gender role change is an accepted part of culture. (medscape.com)
  • In fact, the biggest problem with hormonal birth control is that it causes progesterone deficiency . (larabriden.com)
  • I first heard of the MTHFR ( methylenetetrahydrofolate reductase) enzyme deficiency on the STTM patient-to-patient groups. (stopthethyroidmadness.com)
  • To this end, primary human hepatocytes were treated with estradiol and progesterone, and mRNA expression and activity levels of 10 different P450 isoforms were determined. (aspetjournals.org)
  • Estradiol and progesterone are major female hormones, and their plasma concentrations gradually increase during pregnancy, reaching up to 100 nM and 1 μ M for estradiol and progesterone, respectively, at term. (aspetjournals.org)
  • This leads us to the hypothesis that the balance of estradiol to progesterone and/or to testosterone is an important factor in prostate disease," said Dr. Lee. (cellbone.com)
  • Prostate levels of estradiol begin to rise as men get older - at the same time, levels of progesterone and testosterone decline. (cellbone.com)
  • The decline in testosterone and progesterone levels is greater than the rise of estradiol. (cellbone.com)
  • Estradiol and progesterone levels peak during proestrus after which plummet to their lowest levels during estrus (Becker et al. (deubiquitinaseinhibitor.com)
  • The phase on the estrous cycle can be experimentally determined by measuring serum estradiol and progesterone levels or by evaluating adjustments in vaginal cytology (Becker et al. (deubiquitinaseinhibitor.com)
  • 6 observed that 17-β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), the activity of which transforms oestradiol to less potent oestrogen (oestrone) and is stimulated by progesterone in endometrial glands, was significantly reduced in endometriotic tissue during the luteal phase, along with markedly repressed levels of immunoprecipitable PGR throughout the menstrual cycle. (emjreviews.com)
  • Estrogen and progesterone levels fluctuate naturally for the duration of the primate menstrual cycle plus the rodent estrous cycle. (deubiquitinaseinhibitor.com)
  • What's most important to grasp here is that progesterone is NOT only produced by the ovaries during the menstrual cycle. (heyfreya.co)
  • 2 In an elegant review, Redwine 3 challenged this theory and demonstrated, by analysing a large number of parameters, that endometriosis tissue is primarily reflected dissimilarity than similarity with eutopic endometrium in the uterus, including inadequate secretory differentiation in endometriotic cells under progesterone dominance during the luteal phase. (emjreviews.com)
  • Medical literature cites that about 50 million men and 30 million women in America who exhibit pattern hair loss produce an enzyme called 5-alpha Reductase. (thevitalimage.com)
  • In each phase, your hormones-specifically estrogen, progesterone, and testosterone-can change how you feel and how your body responds to different inputs. (coconutsandkettlebells.com)
  • The hormones in some methods of birth control are similar to the ones female bodies makeclose enough that the body recognizes them as estrogen and progesterone. (healthyhormonesclub.com)
  • Progesterone is what we call the "Mama" hormone because it creates most of the steroid hormones (estrogen, testosterone, and cortisol). (heyfreya.co)
  • From progesterone, all the other steroid hormones are formed. (heyfreya.co)
  • Progesterone is made from cholesterol and is both created and depleted based on which other steroid hormones are being made. (heyfreya.co)
  • The call for increased estrogen production often leads to a drain on the other two hormones, progesterone, and testosterone. (heyfreya.co)
  • Nourishes hair and clears skin because it reduces male hormones (androgens) by inhibiting the enzyme 5-alpha reductase. (larabriden.com)
  • Leu213Gln) in AKR1C1, the gene encoding for an aldo-keto reductase catalyzing the reduction of progesterone to its inactive form, 20-α-hydroxyprogesterone. (magisnat-rd.com)
  • Since progesterone and testosterone stimulate the gene, p53, protection is created from the oncogene (cancer-causing) Bcl-2, and healthy apoptosis (normal cell death) is stimulated. (cellbone.com)
  • In the human, an aldo-keto reductase (AKR) gene family (AKR1C) has been identified near the telomere on chromosome 10p15 that contains at least six aldo-keto reductase family 1, member C genes [ 11 ]. (biomedcentral.com)
  • For PCOS, vitamin C combined with citrus bioflavonoids has been shown to support healthy progesterone levels, stabilize cortisol output, improve fertility, and replenish vitamin C levels which are commonly low in PCOS. (doctorherdmanclinic.com)
  • There's NO progesterone in any type of hormonal birth control. (larabriden.com)
  • If just one of the metabolites is high, his total progesterone in serum may be normal, or the patient could have a metabolic preference pushing the bulk of his metabolites one direction. (healthmatters.io)
  • If oral progesterone OR pregnenolone supplementation are used, please be aware these will increase progesterone metabolites in the urine due to first pass metabolism, but serum progesterone may not be elevated to the same degree as the urine implies. (healthmatters.io)
  • The 5α-reductase inhibitor, N,N-diethyl-4-methyl-3-oxo-4-aza-5α-androstane-17β-carboxamide was injected at a 1 or 2 mg dose/rat 2 h prior to an injection of 0.4 or 0.8 mg progesterone/kg body weight at 0900 h to immature ovariectomized, estrogen-primed rats and serum was analyzed for LH and FSH at 1500 h. (elsevierpure.com)
  • Previous in vivo studies on methoxychlor exposure to female animals have demonstrated decreased progesterone production but no change in serum estrogen levels. (cdc.gov)
  • The current studies examined the mechanism of action of HPTE on progesterone production by cultured ovarian cells (granulosa and theca-interstitial) from pregnant mare serum gonadotropin-primed immature rats. (cdc.gov)
  • Made from cholesterol, pregnenolone is the precursor to progesterone and DHEA, which are. (infopathy.com)
  • Increased levels may be due to high levels of progesterone or pregnenolone, progesterone supplementation, or adrenocorticohyperplasia. (healthmatters.io)
  • The use of the Mirena, Skyla, Liletta, and Kyleena hormonal IUD supplies synthetic progestins in the gonadal area which are going to suppress the body's production of progesterone dramatically. (integrativeaestheticsboston.com)
  • Read The crucial difference between progesterone and progestins . (larabriden.com)
  • Progesterone helps raise testosterone levels, and helps lower the level of the more growth-stimulating DHT. (cellbone.com)
  • It is a viable conclusion that men have good reason to restore the same progesterone and testosterone levels that they had as younger men. (cellbone.com)
  • Taken together, our results show differential effects of estrogen and progesterone on P450 expression, suggesting involvement of different regulatory mechanisms in female hormone-mediated P450 regulation. (aspetjournals.org)
  • Progesterone is known as a female hormone, but males need progesterone to produce testosterone . (aucklandskinclinic.co.nz)
  • Progesterone is a startlingly beneficial hormone, and almost all of us could do with more than we have. (larabriden.com)
  • Progesterone is the hormone of pregnancy and acts on the uterus to stimulate blastocyst survival, growth, and development. (bioscientifica.com)
  • The aim of this paper was to present an overview of different aspects of progesterone resistance and its application in endometriosis. (emjreviews.com)
  • Finally, this article also presents a few important, unmet questions related to the failure of progesterone treatment in alleviating clinical conditions in endometriosis. (emjreviews.com)
  • 3. There is an urgent need for deeper understanding of the cellular and molecular mechanisms of progesterone resistance in endometriosis, for both ectopic and eutopic tissues, to underpin novel approaches to treatment. (emjreviews.com)
  • The fact that progestin treatment fails to regress endometriosis in three out of 10 females is also indicative of inadequate machinery of progesterone action in the endometriotic tissue. (emjreviews.com)
  • Taking these observations together, a theory of 'progesterone resistance' as the mediator of pathogenesis of endometriosis was forwarded in the 2000s. (emjreviews.com)
  • However, HPTE did not change mRNA levels of the P450scc system (P450scc, adrenodoxin reductase and adrenodoxin) as well as P450scc protein levels. (cdc.gov)
  • 5b-pregnanediol is inactive in the body but is the major metabolite of progesterone. (healthmatters.io)
  • 5b-pregnanediol represents the majority end point of endogenous progesterone metabolism and appears to have little activity within the body, while 5α-pregnanediol, the lesser metabolite of PDL, can cross the blood brain barrier and may partially agonize GABA-A receptors. (healthmatters.io)
  • 5A-PD is a minor urinary metabolite of progesterone. (healthmatters.io)
  • The calming action of allopregnanolone is often seen with orally supplemented progesterone, as the liver metabolizes a large portion of oral progesterone to the neuroactive steroid allopregnanolone. (healthmatters.io)
  • Importantly, 5-reductase type I and 3-HSD are expressed within the BLA suggesting that allopregnanolone is locally synthesized (Ag -Balboa et al. (deubiquitinaseinhibitor.com)
  • Progesterone cream is adequate for general symptoms, but capsules are better for perimenopausal sleep problems (oral has greater conversion to allopregnanolone ). (larabriden.com)
  • Take body-identical or natural progesterone , which is available as either a transdermal cream or a capsule. (larabriden.com)
  • In other words, sufficient levels of progesterone may help stop testosterone-related acne and keep skin clear. (coconutsandkettlebells.com)
  • Progesterone keeps 5-alpha-reductase enzyme levels in check, thereby preventing the conversion of Testosterone to DHT (more potent androgen). (aucklandskinclinic.co.nz)
  • Progesterone levels naturally drop in men as they age. (aucklandskinclinic.co.nz)
  • Balanced levels of progesterone act directly by inhibiting the activity of 5-alpha reductase and prevents it from converting testosterone into DHT. (integrativeaestheticsboston.com)
  • When progesterone levels are balanced, it results in DHT levels staying low. (integrativeaestheticsboston.com)
  • Lower levels of pregnanediol may be due to decreased progesterone or 5-alpha reductase activity. (healthmatters.io)
  • Progesterone levels possess a small, secondary peak midway through diestrus I and II whilst estrogen levels rise later to peak as the rodents reenter proestrus. (deubiquitinaseinhibitor.com)
  • Vitamin C as a single chain antioxidant can stop the release of peroxidation processes in the body and support healthy progesterone levels needed for fertility and rhythmic menstrual cycles. (doctorherdmanclinic.com)
  • Symptoms of low progesterone in men include hair loss, low libido, sexual dysfunction, depression, bone and muscle loss. (aucklandskinclinic.co.nz)
  • Progesterone also up-regulates the DAO enzyme and so relieves the anxiety symptoms of histamine intolerance . (larabriden.com)
  • Progesterone also inhibits 5α-reductase , which is required to convert testosterone to the more potent DHT. (coconutsandkettlebells.com)
  • The objective of this study was to comprehensively characterize the effects of estrogen and progesterone on the expression and activity of major drug-metabolizing P450s. (aspetjournals.org)
  • While found in the urine in small amounts, progesterone can be seen as a clinical marker of luteul activity and theraputic oral progesterone administration. (healthmatters.io)
  • Pituitary and hypothalamic 5α-reductase activity was measured at the time of progesterone administration and at the time of the surge by incubating tissue homogenates with [ 3 H]progesterone. (elsevierpure.com)
  • The pituitary 5α-reductase activity was not blocked at 1500 h. (elsevierpure.com)
  • Exposure to HPTE (0, 10, 50 or 100 nM) alone progressively inhibited progesterone formation in cultured theca-interstitial and granulosa cells and the P450scc catalytic activity in theca-interstitial cells in a dose-dependent manner with significant declines starting at 50 nM. (cdc.gov)
  • These studies suggest that the decline in progesterone formation following exposure to HPTE in cultured ovarian cells is associated with the inhibition of catalytic activity of P450scc at least in theca-interstitial cells. (cdc.gov)
  • This would result in a slower and less efficient reduction of progesterone to hydroxyprogesterone and an increased subcutaneous fat deposition in variant carriers. (magisnat-rd.com)
  • This study examined the need of 5α-reduction as a prerequisite for the action of progesterone. (elsevierpure.com)
  • These results indicate a biologically significant role for the irreversible 5α-reduction of progesterone in the modulation of the release of FSH. (elsevierpure.com)
  • Therefore, the main hypothesis was that the aldo-keto reductase (AKR) 1C isoenzymes are responsible for controlling the availability of 17β-oestradiol, progesterone and prostaglandins in the microenvironment of the endometrium, and surrounding adipose tissues of endometriotic lesions and breast tumours. (manchester.ac.uk)
  • progestin treatment fails in a large number of these patients, likely due to progesterone resistance. (emjreviews.com)
  • Co-treatment of HPTE with ICI 182,780 did not block the effect of HPTE on progesterone formation. (cdc.gov)
  • Progesterone does a lot more for you than just fertility and easy periods. (larabriden.com)
  • Progesterone acts on your breasts and uterus, so it's essential for healthy reproduction and periods. (larabriden.com)
  • The cholesterol molecule is the base for all of these, which first turns into progesterone. (heyfreya.co)
  • It is an intermediate in the conversion of progesterone to allopregnalone and isopregnanolone, other common forms of neurosteroids. (wikipedia.org)
  • 7,8 These observations were suggestive of the absence of certain responses to progesterone action. (emjreviews.com)
  • Progesterone is an alpha-reductase competitor and may decrease DHT production in the hair follicle. (maapgh.com)